Etanercept therapy leads to reductions in matrix metalloproteinase-3 in patients with erosive hand osteoarthritis

Scand J Rheumatol. 2020 Mar;49(2):167-168. doi: 10.1080/03009742.2019.1657493. Epub 2019 Sep 30.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Etanercept / therapeutic use*
  • Female
  • Hand
  • Humans
  • Male
  • Matrix Metalloproteinase 3 / blood*
  • Middle Aged
  • Osteoarthritis / drug therapy*
  • Osteoarthritis / enzymology
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Tumor Necrosis Factor-alpha
  • MMP3 protein, human
  • Matrix Metalloproteinase 3
  • Etanercept